Advertisement

Loading...

3D Medicines Inc.

1244.HKHKSE
Healthcare
Biotechnology
HK$4.13
HK$0.10(2.48%)
Hong Kong Market is Open • 10:08

3D Medicines Inc. (1244.HK) Stock Competitors & Peer Comparison

See (1244.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1244.HKHK$4.18+0.00%1B-5.36-HK$0.78N/A
6160.HKHK$174.00+6.03%261.4B116.78HK$1.49N/A
1801.HKHK$85.50+7.68%147.1B161.32HK$0.53N/A
2269.HKHK$32.36+2.60%133.8B24.52HK$1.32N/A
9926.HKHK$126.40+2.18%116.3B-115.96-HK$1.09N/A
1177.HKHK$5.89+1.20%105.3B39.27HK$0.15+1.53%
1530.HKHK$23.98+10.41%56.6B22.00HK$1.09+1.04%
9995.HKHK$94.15+6.26%51.7B-39.39-HK$2.39N/A
3759.HKHK$18.53+4.10%50.6B19.10HK$0.97+1.18%
2696.HKHK$71.70+8.64%39B41.69HK$1.72N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1244.HK vs 6160.HK Comparison April 2026

1244.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1244.HK stands at 1B. In comparison, 6160.HK has a market cap of 261.4B. Regarding current trading prices, 1244.HK is priced at HK$4.18, while 6160.HK trades at HK$174.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1244.HK currently has a P/E ratio of -5.36, whereas 6160.HK's P/E ratio is 116.78. In terms of profitability, 1244.HK's ROE is -0.22%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 1244.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1244.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions